Evidence map›Paper›PMID 35158809›Full record

ArticleCancers2022

Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management.

Michael Schwake, Michael Müther, Ann-Katrin Bruns, Bastian Zinnhardt, Nils Warneke, Markus Holling, Stephanie Schipmann, Benjamin Brokinkel, Johannes Wölfer, Walter Stummer and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Michael SchwakeDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.
Michael MütherDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0001-9427-5555
Ann-Katrin BrunsDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.
Bastian ZinnhardtEuropean Institute for Molecular Imaging (EIMI), University of Münster, 48149 Münster, Germany.
Nils WarnekeDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.
Markus HollingDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0002-2167-0789
Stephanie SchipmannDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.
Benjamin BrokinkelDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.
Johannes WölferDeparment of Neurosurgery, Hufeland Klinikum, 99974 Mühlhausen, Germany.
Walter StummerDepartment of Neurosurgery, University Hospital Münster, 48149 Münster, Germany.
Oliver GrauerDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0003-4279-4497
University Hospital Münster · DEHaukeland University Hospital · NORoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConcepts improving local tumor control in high-grade glioma (HGG) are desperately needed. The aim of this study is to report an extended series of cases treated with a combination of 5-ALA-fluorescence-guided resection (FGR) and intracavitary thermotherapy with superparamagnetic iron oxide nanoparticles (SPION).

methodsWe conducted a single-center retrospective review of all recurrent HGG treated with FGR and intracavitary thermotherapy (

resultsNine patients were treated for first tumor recurrence; all other patients had suffered at least two recurrences. Nine patients received combined radiotherapy and thermotherapy. The median progression-free survival was 5.5 (95% CI: 4.67-6.13) months and median overall survival was 9.5 (95% CI: 7.12-11.79) months. No major side effects were observed during active treatment. Thirteen patients (72%) developed cerebral edema and more clinical symptoms during follow-up and were initially treated with dexamethasone. Six (33%) of these patients underwent surgical removal of nanoparticles due to refractory edema.

conclusionsThe combination of FGR and intracavitary thermotherapy with SPION provides a new treatment option for improving local tumor control in recurrent HGG. The development of cerebral edema is a major issue requiring further refinements of the treatment protocol.

Indexed as

fluorescencegliomainflammationmyeloid cellsnanoparticlesthermotherapy

Identifiers

PMID35158809
PMCPMC8833446
OpenAlexW4212874259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.